FlowMorph: Physics-Consistent Self-Supervision for Label-Free Single-Cell Mechanics in Microfluidic Videos

Abstract

Mechanical properties of red blood cells (RBCs) are promising biomarkers for hematologic and systemic disease, motivating microfluidic assays that probe deformability at throughputs of 103--106 cells per experiment. However, existing pipelines rely on supervised segmentation or hand-crafted kymographs and rarely encode the laminar Stokes-flow physics that governs RBC shape evolution. We introduce FlowMorph, a physics-consistent self-supervised framework that learns a label-free scalar mechanics proxy k for each tracked RBC from short brightfield microfluidic videos. FlowMorph models each cell by a low-dimensional parametric contour, advances boundary points through a differentiable ''capsule-in-flow'' combining laminar advection and curvature-regularized elastic relaxation, and optimizes a loss coupling silhouette overlap, intra-cellular flow agreement, area conservation, wall constraints, and temporal smoothness, using only automatically derived silhouettes and optical flow. Across four public RBC microfluidic datasets, FlowMorph achieves a mean silhouette IoU of 0.905 on physics-rich videos with provided velocity fields and markedly improves area conservation and wall violations over purely data-driven baselines. On 1.5× 105 centered sequences, the scalar k alone separates tank-treading from flipping dynamics with an AUC of 0.863. Using only 200 real-time deformability cytometry (RT-DC) events for calibration, a monotone map E=g(k) predicts apparent Young's modulus with a mean absolute error of 0.118\,MPa on 600 held-out cells and degrades gracefully under shifts in channel geometry, optics, and frame rate.

0

Turn this paper into a full lesson

ArcXiv compiles a staged curriculum from this paper: 8-12 lessons across beginner → advanced, synthesised section guides, visuals, flashcards, a quiz, exercises, and on-demand deep dives per section. Grounded in the abstract, never invented.

Discussion (0)

Sign in to join the discussion.

Loading comments…